Molecular Regulation of Androgen Receptors in Major Female Reproductive System Cancers

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jul 27

PMID 35886904

Authors

Sujun Wu

Kun Yu

Zhengxing Lian

Shoulong Deng

Affiliations

Soon will be listed here.

Abstract

There are three main types of cancer in the female reproductive system, specifically ovarian cancer (OVCA), endometrial cancer (EC), and cervical cancer (CC). They are common malignant tumors in women worldwide, with high morbidity and mortality. In recent years, androgen receptors (ARs) have been found to be closely related to the occurrence, progression, prognosis, and drug resistance of these three types of tumors. This paper summarizes current views on the role of AR in female reproductive system cancer, the associations between female reproductive system cancers and AR expression and polymorphisms. AR regulates the downstream target genes transcriptional activity and the expression via interacting with coactivators/corepressors and upstream/downstream regulators and through the gene transcription mechanism of "classical A/AR signaling" or "non-classical AR signaling", involving a large number of regulatory factors and signaling pathways. ARs take part in the processes of cancer cell proliferation, migration/invasion, cancer cell stemness, and chemotherapeutic drug resistance. These findings suggest that the AR and related regulators could target the treatment of female reproductive system cancer.

Citing Articles

A single-cell network approach to decode metabolic regulation in gynecologic and breast cancers.

Srivastava A, Vinod P NPJ Syst Biol Appl. 2025; 11(1):26.

PMID: 40082472 PMC: 11906788. DOI: 10.1038/s41540-025-00506-0.

Effects of Isoxazolyl Steroids on Key Genes of Sonic Hedgehog Cascade Expression in Tumor Cells.

Aleksandrova A, Mekhtiev A, Timoshenko O, Kugaevskaya E, Gureeva T, Gisina A Molecules. 2024; 29(17).

PMID: 39274874 PMC: 11396458. DOI: 10.3390/molecules29174026.

Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors.

Alam S, Giri P Cancer Drug Resist. 2024; 7:6.

PMID: 38434767 PMC: 10905178. DOI: 10.20517/cdr.2023.152.

Genetically predicted serum testosterone and risk of gynecological disorders: a Mendelian randomization study.

Zhao B, Wang Z, Liu D, Zhang S Front Endocrinol (Lausanne). 2023; 14:1161356.

PMID: 38075074 PMC: 10710168. DOI: 10.3389/fendo.2023.1161356.

Melatonin in Chemo/Radiation Therapy; Implications for Normal Tissues Sparing and Tumor Suppression: An Updated Review.

Gupta J, Almulla A, Turki Jalil A, Jasim N, Aminov Z, Alsaikhan F Curr Med Chem. 2023; 32(3):511-538.

PMID: 37916636 DOI: 10.2174/0109298673262122231011172100.

References

Du F, Li Y, Zhang W, Kale S, McFerrin H, Davenport I . Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression. Tumour Biol. 2016; 37(8):11147-11162. PMC: 5292133. DOI: 10.1007/s13277-015-4518-4. View

McGrath M, Lee I, Hankinson S, Kraft P, Hunter D, Buring J . Androgen receptor polymorphisms and endometrial cancer risk. Int J Cancer. 2005; 118(5):1261-8. DOI: 10.1002/ijc.21436. View

He L, Wang H, Zhang L, Huang L, Li J, Xiong Y . Prognostic significance of low DICER expression regulated by miR-130a in cervical cancer. Cell Death Dis. 2014; 5:e1205. PMC: 4047899. DOI: 10.1038/cddis.2014.127. View

McEwan I . Molecular mechanisms of androgen receptor-mediated gene regulation: structure-function analysis of the AF-1 domain. Endocr Relat Cancer. 2004; 11(2):281-93. DOI: 10.1677/erc.0.0110281. View

Clinckemalie L, Vanderschueren D, Boonen S, Claessens F . The hinge region in androgen receptor control. Mol Cell Endocrinol. 2012; 358(1):1-8. DOI: 10.1016/j.mce.2012.02.019. View

Jardim D, Millis S, Ross J, Woo M, Ali S, Kurzrock R . Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions. Oncologist. 2020; 26(1):e78-e89. PMC: 7794175. DOI: 10.1634/theoncologist.2020-0509. View

Friedenreich C, Derksen J, Speidel T, Brenner D, Heer E, Courneya K . Case-control study of endogenous sex steroid hormones and risk of endometrial cancer. Cancer Causes Control. 2019; 31(2):161-171. DOI: 10.1007/s10552-019-01260-5. View

Rao B, Slotman B . Endocrine factors in common epithelial ovarian cancer. Endocr Rev. 1991; 12(1):14-26. DOI: 10.1210/edrv-12-1-14. View

Bao W, Wang H, Tian F, He X, Qiu M, Wang J . A TrkB-STAT3-miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells. Mol Cancer. 2013; 12:155. PMC: 3879200. DOI: 10.1186/1476-4598-12-155. View

10.

Butler M, Ricciardelli C, Tilley W, Hickey T . Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression. Horm Cancer. 2013; 4(3):154-64. PMC: 10358082. DOI: 10.1007/s12672-013-0135-0. View

11.

Tang D, Dai Y, He J, Lin L, Leng Q, Geng X . Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer. J Pathol. 2020; 252(2):101-113. DOI: 10.1002/path.5495. View

12.

Tangen I, Onyango T, Kopperud R, Berg A, Halle M, Oyan A . Androgen receptor as potential therapeutic target in metastatic endometrial cancer. Oncotarget. 2016; 7(31):49289-49298. PMC: 5226508. DOI: 10.18632/oncotarget.10334. View

13.

Lortet-Tieulent J, Ferlay J, Bray F, Jemal A . International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013. J Natl Cancer Inst. 2017; 110(4):354-361. DOI: 10.1093/jnci/djx214. View

14.

Ludwig A, Murawska M, Panek G, Timorek A, Kupryjanczyk J . Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome. Endocr Relat Cancer. 2009; 16(3):1005-16. DOI: 10.1677/ERC-08-0135. View

15.

Lai K, Huang C, Chang Y, Chung C, Yamashita S, Li L . New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol. 2012; 182(2):460-73. PMC: 3562731. DOI: 10.1016/j.ajpath.2012.10.029. View

16.

Chung W, Chang W, Chen L, Lin T, Chen L, Hung Y . Ligand-independent androgen receptors promote ovarian teratocarcinoma cell growth by stimulating self-renewal of cancer stem/progenitor cells. Stem Cell Res. 2014; 13(1):24-35. DOI: 10.1016/j.scr.2014.04.003. View

17.

Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C . A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer. 2007; 110(11):2448-56. DOI: 10.1002/cncr.23072. View

18.

Carmen M . Evidence for the Relationship Between Endometriosis and Epithelial Ovarian Cancer. Obstet Gynecol Surv. 2015; 70(9):587-95. DOI: 10.1097/OGX.0000000000000218. View

19.

Thomas S, Brugge J . Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997; 13:513-609. DOI: 10.1146/annurev.cellbio.13.1.513. View

20.

Geistlinger L, Oh S, Ramos M, Schiffer L, LaRue R, Henzler C . Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma. Cancer Res. 2020; 80(20):4335-4345. PMC: 7572645. DOI: 10.1158/0008-5472.CAN-20-0521. View